Trials / Terminated
TerminatedNCT03680053
Comparison of the Live Birth Rate Between the PPOS and the GnRH Antagonist Protocol in Patients Undergoing IVF
A Randomized Comparison of the Live Birth Rate Between the Progestin-primed Ovarian Stimulation Protocol and the Gonadotrophin Releasing Hormone Antagonist Protocol in Patients Undergoing in Vitro Fertilization
- Status
- Terminated
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 220 (actual)
- Sponsor
- ShangHai Ji Ai Genetics & IVF Institute · Academic / Other
- Sex
- Female
- Age
- 20 Years – 43 Years
- Healthy volunteers
- Not accepted
Summary
A randomized comparison of the live birth rate between the progestin-primed ovarian stimulation protocol and the gonadotrophin releasing hormone antagonist protocol in patients undergoing in vitro fertilization Research question Does the live birth rate of the progestin-primed ovarian stimulation protocol comparable with the GnRH antagonist protocol for patients undergoing IVF? Design This is a randomized controlled trial. Research plan Population: Infertile women who have medical indication for IVF will be recruited for study if they fulfil the selection criteria. Intervention: Women will receive oral dydrogesterone 20mg daily from Day 3 till the day of ovulation trigger. Comparator: Women will receive antagonist (Cetrorelix 0.25mg) once subcutaneously daily from day 6 of ovarian stimulation till the day of the ovulation trigger. Outcomes: The primary outcome is the live birth rate the first FET. Ovarian stimulation, egg retrieval, embryos frozen and frozen embryo transfer will be performed according to the standard operating procedures of the centres.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Duphaston | Women will receive oral duphaston 20mg daily from Day 3 till the day of ovulation trigger. |
| DRUG | Cetrorelix | Women will receive antagonist (Cetrorelix 0.25mg) once subcutaneously daily from day 6 of ovarian stimulation till the day of the ovulation trigger. |
Timeline
- Start date
- 2020-04-10
- Primary completion
- 2025-05-10
- Completion
- 2025-05-10
- First posted
- 2018-09-21
- Last updated
- 2025-05-31
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT03680053. Inclusion in this directory is not an endorsement.